Psychedelic Therapies at a Turning Point: How Recent Federal Actions May Reshape Psychiatric Care
After years of significant research barriers and limited governmental support, recent federal actions have placed psychedelic-assisted therapies for the treatment of serious mental illness back into focus. But will these regulatory changes lead to approved agents, and how do they impact clinical practice?
Psych Congress Network spoke with Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, to discuss why these regulatory actions could mark an inflection point for psychedelic psychiatry and how these developments may influence clinical practice.
Key Takeaways for Clinical Practice:
- Despite the 2024 FDA rejection of a New Drug Application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD), current psychedelic trials are more rigorous and aligned with FDA standards.
- FDA priority review vouchers for Compass Pathways, Usona Institute, and Transcend Therapeutics may speed review timelines but do not alter standard approval requirements.
- President Trump’s executive order may streamline coordination and timelines, with experts suggesting possible clinical availability within ~12 months pending positive phase 3 data.
FDA Voucher Program and Executive Order Accelerate Psychedelic Drug Development
The 2024 US Food and Drug Administration (FDA) rejection of Lykos Therapeutics’ new drug application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD) slowed momentum for psychedelic-based psychiatric treatment.
However, Dr Raison noted that the research conducted by the 3 companies that have received FDA vouchers for accelerated review of psychedelic therapies—Compass Pathways, Usona Institute, and Transcend Therapeutics—has been more rigorously designed and aligned with FDA expectations.
“It is true that Lykos also had two phase 3 studies for MDMA for PTSD and was denied approval a couple of years ago,” Dr Raison said. “But unlike Lykos, the Compass studies have, from the beginning, been conducted in a manner that will make the FDA much more likely to approve them.”
The federal government’s role in driving this initiative also signals an important shift from longstanding regulatory and research constraints.
“Because of the complex history of psychedelics in both medicine and the culture, and their legal status as Schedule 1 substances, conducting rigorous scientific research has been difficult for many reasons,” added Penn. “This executive order has the potential to expedite the coordination that will have to occur between drug developers and federal agencies needed to move these drugs from research laboratory to clinic.”
Implications for Clinical Practice
While the executive order and voucher program promise to accelerate the review process for psychedelic agents, all investigational drugs will still be subjected to the FDA’s standard review and approval process.
“The FDA Commissioner’s voucher program only moves these 3 companies and their compounds up in the review line at the FDA,” Penn noted. “It does not guarantee their approval.”
This also means that these psychedelic agents are not immediately available or approved for use in practice. However, several of the drugs under investigation are nearing the end of phase 3 studies, including psilocybin-based therapies for treatment-resistant depression (TRD) and major depressive disorder (MDD).
With the accelerated approval process, “it’s looking more likely that 1 or more of these compounds will be available for clinical use in the next year or so,” Penn said.
Opportunities for Education: Expert Briefing With Psych Congress Faculty
To address clinicians’ questions about the implications of these federal actions, Psych Congress is hosting a free webinar led by Dr Raison and Penn, tonight, April 29th at 6:00 PM EST. In a Q&A format, the presentation will cover anticipated approval timelines, strategies for discussing psychedelic therapies with patients, and what mental health clinicians can expect moving forward.
Prepare for the next phase of psychedelic psychiatry in clinical practice. Register now!
